Rethinking Clinical Trials

MARCH 1, 2023

They are both approved and used widely in lung cancer, and combining two existing agents is logistically and clinically simpler. S1800A was a Phase II randomized study of ramucirumab plus pembrolizumab versus standard of care for NSCLC patients previously treated with immunotherapy performed within the Lung-MAP platform.

Clinical Trials 130

Clinical Trials Clinical Trials Trials Packaging 130

Rethinking Clinical Trials

FEBRUARY 14, 2024

The study started in June 2016 and ended in June 2022 and ultimately found no difference between the 2 drugs in preventing major CV outcomes and non-cancer death among hypertensive VA patients. The VA IRB determined DCP was a minimal risk study, with less restrictive eligibility criteria and EHR-based safety and outcome monitoring.

Clinical Trials 162

Clinical Trials Clinical Trials Cardiology Trials 162

Rethinking Clinical Trials

OCTOBER 2, 2023

PROTEUS and Pfizer partnered to form an Advisory Group that aimed to improve understanding of the facilitators and barriers of implementing routine PRO assessments in vulnerable and underserved populations and build capacity for PRO implementation to improve care for cancer patients who are vulnerable or underserved.

Clinical Trials 162

Clinical Trials Clinical Trials Research Trials 162

Rethinking Clinical Trials

OCTOBER 26, 2023

Untreated, chronic Hepatitis C infection leads to liver damage, liver cancer, and death. with the rate of reported acute Hepatitis C cases increasing 400% during 2010-2020. with the rate of reported acute Hepatitis C cases increasing 400% during 2010-2020. Rates are the highest among 20-39-year-olds.

Clinical Research 147

Clinical Research Clinical Trials Clinical Trials Research 147

pharmaphorum

OCTOBER 21, 2021

There are also a number of medical Twitter chats during which HCPs collaborate on issues more broadly than medical journals, such as #PancChat – a Twitter chat “ developed to provide relevant , credible, and timely information to the [pancreatic cancer] community”. Threads: healthcare community embraces new Twitter feature.

Doctors 125

Doctors Doctor Trials Research 125

Roots Analysis

NOVEMBER 3, 2023

One of the main challenges is the development of drug resistance, as cancer cells can develop mechanisms to bypass the inhibition of NAMPT. As a starting point, the information on terminated, suspended and withdrawn trials was collated from clinicaltrials.gov and PubMed using relevant search keywords.

Development 40

Development Drugs Trials FDA Approval 40

Rethinking Clinical Trials

MARCH 21, 2023

Goldberg Distinguished Professor and Chief of Oncology Physician-in-Chief, North Carolina Cancer Hospital Director, Cancer Outcomes Research Program University of North Carolina Slides Keywords Patient-reported outcomes, Oncology, Clinical Trials Key Points Symptoms are common in cancer care.

Clinical Trials 130

Clinical Trials Clinical Trials Trials Research 130